retatrutide type 2 diabetes phase 2 results 2024 2025 Lilly's triple agonist achieves 16.8% weight loss in 3 trial retatrutide phase 2 trial type

Suggested use

A total of 478 patients were randomized into equally sized four study arms

Compounded medications are not required to go through the same clinical testing processes overseen by the FDA

Potential side effects of GLP-1s include nausea, vomiting, changes in vision, low blood sugar, and, in rare cases, thyroid cancer

activation remains weeks 14

FuturHealth asks validated PHQ-2 depression items, a dedicated family-history MEN-2 and medullary thyroid cancer screen, pregnancy and breastfeeding, suicidal thoughts, eating-disorder disqualifiers, medication allergies, blood pressure stages, resting heart rate, family heart-disease history, three separate comorbidity screens, bariatric surgery history, and a federal-payer ineligibility check